Literature DB >> 312489

Physical growth in phenylketonuria: I. A retrospective study.

V A Holm, W E Knox.   

Abstract

A retrospective cross-sectional survey of phenylketonuria (PKU) was conducted in 1967. Questionnaires on 693 patients, clinically thought to have PKU, were reanalyzed to obtain information on growth in height and head circumference in patients with untreated and previously treated PKU. To provide a comparison to the growth findings of the Collaborative PKU Study, a definition of PKU was adopted to correspond to the one used in that study. Stature in 232 outpatients with untreated PKU was normal but, in 31 institutionalized individuals, the mean height was -1.4 standard deviations below the mean of a normal population. Head circumference in patients with untreated PKU was normal at birth, but showed an increasingly negative deviance with age and was -1.4 SD in untreated adults. Height measurements of 135 children with PKU in whom treatment was started before 121 days of age (age chosen to coincide with criteria for the Collaborative Study) had a significant reduction in height growth, -.8 SD. Head circumference measurements of 115 children treated for PKU were -.7 SD of normal. The depression in head circumference was less in treated subjects with PKU than in untreated ones of the same age. These findings are corroborated by a review of the literature, which contains no convincing report of normal growth during treatment of PKU.

Entities:  

Mesh:

Year:  1979        PMID: 312489

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  5 in total

1.  Using change in plasma phenylalanine concentrations and ability to liberalize diet to classify responsiveness to tetrahydrobiopterin therapy in patients with phenylketonuria.

Authors:  Rani H Singh; Meghan E Quirk
Journal:  Mol Genet Metab       Date:  2011-09-16       Impact factor: 4.797

2.  Myelin turnover in hyperphenylalaninaemia. A re-evaluation with the HPH-5 mouse.

Authors:  F A Hommes; L Moss
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

3.  Impaired prenatal and postnatal growth in Dutch patients with phenylketonuria. The National PKU Steering Committee.

Authors:  P H Verkerk; F J van Spronsen; G P Smit; R C Sengers
Journal:  Arch Dis Child       Date:  1994-08       Impact factor: 3.791

4.  Long-Term Growth in Phenylketonuria: A Systematic Review and Meta-Analysis.

Authors:  Fatma Ilgaz; Alex Pinto; Hülya Gökmen-Özel; Julio César Rocha; Esther van Dam; Kirsten Ahring; Amaya Bélanger-Quintana; Katharina Dokoupil; Erdem Karabulut; Anita MacDonald
Journal:  Nutrients       Date:  2019-09-03       Impact factor: 5.717

5.  Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at < 4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial.

Authors:  Ania C Muntau; Alberto Burlina; François Eyskens; Peter Freisinger; Vincenzo Leuzzi; Hatice Serap Sivri; Gwendolyn Gramer; Renata Pazdírková; Maureen Cleary; Amelia S Lotz-Havla; Paul Lane; Ignacio Alvarez; Frank Rutsch
Journal:  Orphanet J Rare Dis       Date:  2021-08-03       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.